A biopharmaceutical company focused on novel drug discovery
Total raised: $45M
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| - | Series C | $45M | - |
Mentions in press and media 2
| Date | Title | Description |
| 18.03.2024 | KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1 | -- Tunlametinib is poised to be a potential best-in-class MEK inhibitor based on positive data from the pivotal Phase 2 study SHANGHAI, March 18, 2024 /PRNewswire/ -- KeChow Pharma, a commercial-stage pharmaceutical company focused on devel... |
| - | Chinese Biopharmaceutical Firm KeChow Pharma Closes on $45M Series C Funding Round | - |